| Active principles | Rating | Bibliogr. | Expand |
---|
1 | Meclizine | 100 | + | |
2 | Vitamin A | 12 | + | |
3 | Eye Proteins | 7 | + | |
4 | Ivermectin | 6 | + | |
5 | cis-trans-Isomerases | 6 | + | |
6 | Interferon-beta | 5 | + | |
7 | Rhodopsin | 5 | + | |
8 | Retinaldehyde | 5 | + | |
9 | Lipofuscin | 4 | + | |
10 | beta Carotene | 3 | + | |
11 | DNA, Complementary | 3 | + | |
12 | Glucocorticoids | 3 | + | |
13 | Vascular Endothelial Growth Factor A | 3 | + | |
14 | Dystrophin | 3 | + | |
15 | Phytanic Acid | 3 | + | |
16 | Aptamers, Nucleotide | 3 | + | |
17 | Crystallins | 2 | + | |
18 | Antibodies, Monoclonal, Humanized | 2 | + | |
19 | Serpins | 2 | + | |
20 | Azithromycin | 2 | + | |
21 | Adrenal Cortex Hormones | 2 | + | |
22 | Methylphenidate | 2 | + | |
23 | Levodopa | 2 | + | |
24 | Morpholinos | 2 | + | |
25 | Porphyrins | 2 | + | |
26 | Piracetam | 2 | + | |
27 | Antibodies, Monoclonal | 2 | + | |
28 | Selegiline | 1 | + | |
29 | Glycosylation End Products, Advanced | 1 | + | |
30 | Oligonucleotides, Antisense | 1 | + | |
31 | Codon, Nonsense | 1 | + | |
32 | RNA Splice Sites | 1 | + | |
33 | Botulinum Toxins, Type A | 1 | + | |
34 | Vascular Endothelial Growth Factors | 1 | + | |
35 | Oxygen | 1 | + | |
36 | Methylprednisolone | 1 | + | |
37 | Oligoribonucleotides, Antisense | 1 | + | |
38 | Lidocaine | 1 | + | |
39 | RNA Precursors | 1 | + | |
40 | Riboflavin | 1 | + | |
41 | Viral Regulatory and Accessory Proteins | 1 | + | |
42 | Tryptamines | 1 | + | |
43 | Fragile X Mental Retardation Protein | 1 | + | |
44 | Immunoglobulins, Intravenous | 1 | + | |
45 | Viral Proteins | 1 | + | |
46 | Crotonates | 1 | + | |
47 | Botulinum Toxins | 1 | + | |
48 | Steroids | 1 | + | |
49 | Oligoclonal Bands | 1 | + | |
50 | DNA Transposable Elements | 1 | + | |
51 | Plastics | 1 | + | |
52 | Peptides | 1 | + | |
53 | Phenethylamines | 1 | + | |
54 | Insulin | 1 | + | |
55 | 2,3-Diketogulonic Acid | 1 | + | |
56 | Triamcinolone Acetonide | 1 | + | |
57 | Recombinant Proteins | 1 | + | |
58 | Epinephrine | 1 | + | |